AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD ...

Lokelma (sodium zirconium cyclosilicate) will compete with Vifor Pharma group member Relypsa’s rival Veltassa (patiromer), which has been on the market for a few years in the US and Europe.

Lokelma is used for the treatment of hyperkalaemia, a condition characterized by elevated potassium levels in the blood. It is an adult drug used for those with high potassium and are marketed ...